SCHEMBL6991507

SCHEMBL6991507

CC(C)(C)OC(=O)NCCCc1cccnc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NQO2 P16083 1/20 0.48
CYP3A4 P08684 1/20 0.47
CA1 P00915 5/20 0.44
CA2 P00918 5/20 0.44
CA12 O43570 4/20 0.44
CA9 Q16790 4/20 0.44
TDP1 Q9NUW8 2/20 0.44
STK17B O94768 1/20 0.43
STK17A Q9UEE5 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTT P42858 1/20 0.41
BCHE P06276 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6554649 0.92 NQO2 (0.56) KDM4EL3MBTL1NQO2CYP3A4CA1
SCHEMBL6994097 0.86 CYP3A4 (0.47) KDM4EL3MBTL1NQO2CYP3A4CA1
SCHEMBL23177724 0.84 CA1 (0.47) KDM4EL3MBTL1NQO2CYP3A4CA1
SCHEMBL15804093 0.84 NAMPT (0.46) KDM4EL3MBTL1NQO2CYP3A4GAA
SCHEMBL28881731 0.83 CYP3A4 (0.44) KDM4EL3MBTL1NQO2CYP3A4CA1
SCHEMBL12667243 0.82 TDP1 (0.46) KDM4EL3MBTL1NQO2CYP3A4CA1
SCHEMBL8600783 0.81 NQO2 (0.52) NQO2CA1CA2CA12CA9
SCHEMBL12634899 0.79 TDP1 (0.60) NQO2CA1CA2CA12CA9
SCHEMBL16158175 0.79 TDP1 (0.53) NQO2CYP3A4CA1CA2CA12
SCHEMBL30898271 0.79 TDP1 (0.53) NQO2CYP3A4CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303488-A1 PIPERIDINE COMPOUNDS FOR USE AS CCR-3 INHIBITORS Novartis AG (CH) 2003-04-23 EP disclosed
WO-2002004420-A1 PIPERIDINE COUMPOUNDS FOR USE AS CCR-3 INHIBITORS NOVARTIS AG (CH) 2002-01-17 WO disclosed